Merck EBITDA 2012-2026 | MRK

Merck EBITDA for the quarter ending March 31, 2026 was $7.708B, a 49.09% increase year-over-year.

  • Merck 2024 EBITDA was 24.72B, a 262.14% increase from 2023.
  • Merck 2023 EBITDA was 6.826B, a 69.24% decline from 2022.
  • Merck 2022 EBITDA was 22.191B, a 35.2% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Merck EBITDA 2012-2026 | MRK

  • Merck 2024 EBITDA was 24.72B, a 262.14% increase from 2023.
  • Merck 2023 EBITDA was 6.826B, a 69.24% decline from 2022.
  • Merck 2022 EBITDA was 22.191B, a 35.2% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B